Why Pinterest Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Portfolio Pulse from Lisa Levin
Several stocks are experiencing significant pre-market movements. LumiraDx Limited (LMDX) surged 38.8% after a Nasdaq delisting determination. TransCode Therapeutics (RNAZ) gained 30.1% after withdrawing a public offering. Pinterest (PINS) rose 16.5% following better-than-expected Q3 results and guidance. Wolfspeed (WOLF) rose 14.9% after Q1 earnings. On the downside, Sarepta Therapeutics (SRPT) fell 45.4% after reporting topline results from a pivotal study. PetMed Express (PETS) dipped 26.8% after weaker-than-expected Q2 sales.
October 31, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LumiraDx shares surged after a Nasdaq delisting determination.
The surge in LumiraDx's stock price is likely due to the Nasdaq delisting determination, which may have sparked investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pinterest rose following better-than-expected Q3 results and guidance.
Pinterest's stock price rose likely due to better-than-expected Q3 results and guidance, which may have boosted investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
TransCode Therapeutics gained after withdrawing a public offering.
TransCode's stock price increased likely due to the withdrawal of a public offering, which may have been viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Wolfspeed rose after reporting Q1 earnings.
Wolfspeed's stock price rose likely due to the company's Q1 earnings report, which may have been viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
PetMed Express dipped after weaker-than-expected Q2 sales.
PetMed's stock price dipped likely due to weaker-than-expected Q2 sales, which may have disappointed investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Sarepta Therapeutics fell after reporting topline results from a pivotal study.
Sarepta's stock price fell likely due to the company's topline results from a pivotal study, which may have been viewed negatively by investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100